Schizophrenia – Current Treatment – Current Treatment: Physician Insights – Schizophrenia (US)
In the United States, atypical antipsychotics available in oral and injectable (e.g., long-acting injectable [LAI]) formulations are the mainstay of schizophrenia treatment. However, the dearth of effective therapies to treat the negative symptoms and cognitive impairment associated with the disease leaves substantial unmet need. Given the availability of newer, more-tolerable oral atypical antipsychotics (e.g., Intra-Cellular Therapies’ Caplyta) and newer LAIs offering dosing flexibility among other advantages (e.g., Otsuka/Lundbeck’s Abilify Asimtufii), the clinical heterogeneity of schizophrenia, and patients’ varied responses to antipsychotic therapy, the treatment landscape is undergoing conspicuous changes. Multiple factors such as tolerability, compliance, market access, clinical profile, route, and frequency of administration appeal differentially to patients and psychiatrists alike when making treatment choices. Understanding the prescribing patterns in this space and the challenges that psychiatrists face treating this disease is indispensable for marketers of current branded therapies (e.g., AbbVie’s Vraylar, Johnson & Johnson Innovative Medicine’s Invega Trinza, Otsuka/Lundbeck’s Abilify Maintena) and for developers of emerging therapies.
- What percentage of schizophrenia patients are on antipsychotic treatment, and what is the patient share of individual therapies?
- How are patients treated in different lines of therapy, and what drives the switching to specific brands?
- When and why do psychiatrists introduce antipsychotic LAIs into their patients’ treatment?
- What percentage of patients present with negative symptoms and/or cognitive impairment, and how are they treated?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Geography: United States.
Primary Research: Survey of 101 U.S. psychiatrists
Key companies: AbbVie, Alkermes, Johnson & Johnson Innovative Medicine, Indivior, Intra-Cellular Therapies, Lundbeck, Otsuka, Sumitomo Pharma / Sunovion Pharmaceuticals, Teva, Luye Pharma
Key drugs covered: Abilify Maintena, Abilify Asimtufii, Invega Hafyera, Aristada, Invega Sustenna, Invega Trinza, Rexulti, Uzedy, olanzapine, clozapine, Vraylar, Caplyta, Lybalvi, Rykindo
Key insights provided
- Factors influencing disease management and treatment decisions
- Drivers and constraints of treatment selection
- Physician-reported treatment practices and brand-level patient shares
- Rationale for changes in treatment approach
- Physician insight on persistency and compliance
- Physician-reported recent / anticipated changes in brand usage or treatment approach
